Compagnie Lombard Odier SCmA’s Apellis Pharmaceuticals APLS Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,000	Closed	-$249K	–	423
2025 Q3	$249K	Hold	11,000	–	–	﹤0.01%	240
2025 Q2	$190K	Hold	11,000	–	–	﹤0.01%	244
2025 Q1	$241K	Hold	11,000	–	–	﹤0.01%	242
2024 Q4	$351K	Hold	11,000	–	–	0.01%	202
2024 Q3	$317K	Hold	11,000	–	–	﹤0.01%	207
2024 Q2	$422K	Buy	11,000 +7,000	+175%	+$317K	0.01%	191
2024 Q1	$235K	Hold	4,000	–	–	﹤0.01%	242
2023 Q4	$239K	Hold	4,000	–	–	﹤0.01%	266
2023 Q3	$152K	Hold	4,000	–	–	﹤0.01%	308
2023 Q2	$364K	Hold	4,000	–	–	0.01%	195
2023 Q1	$264K	Sell	4,000 -500	-11%	-$28.9K	0.01%	250
2022 Q4	$233K	Hold	4,500	–	–	0.01%	272
2022 Q3	$307K	Sell	4,500 -4,500	-50%	-$266K	0.01%	254
2022 Q2	$407K	Hold	9,000	–	–	0.01%	222
2022 Q1	$457K	Hold	9,000	–	–	0.01%	218
2021 Q4	$426K	Hold	9,000	–	–	0.01%	261
2021 Q3	$297K	Hold	9,000	–	–	0.01%	304
2021 Q2	$569K	Sell	9,000 -376,795	-98%	-$19.4M	0.01%	212
2021 Q1	$16.6M	Buy	385,795 +382,795	+12,760%	+$18.1M	0.36%	56
2020 Q4	$172K	Buy	+3,000	New	+$127K	﹤0.01%	344

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Compagnie Lombard Odier SCmA's APLS Position: Q4 2025 in Review

Compagnie Lombard Odier SCmA sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 11,000 shares — an estimated $249K sold.

Compagnie Lombard Odier SCmA first reported a position in APLS in Q4 2020 and held it in 20 quarters. The position peaked at $16.6M in Q1 2021. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

Compagnie Lombard Odier SCmA reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 11,000 Apellis Pharmaceuticals shares in Q4 2025, an estimated $249K.
Compagnie Lombard Odier SCmA first reported a position in Apellis Pharmaceuticals in Q4 2020 and held it in 20 quarters.
Compagnie Lombard Odier SCmA's Apellis Pharmaceuticals position peaked at $16.6M in Q1 2021.
279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2025, filed 16 Jan 2026.